Trial
NCT03218163
MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
—
Condition
Multiple Myeloma
Intervention
MEDI-551 Maintenance
Why stopped
MEDI-551 removed from oncology by pharmaceutical company due to change in research target.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-14